Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | -24.68%25.93K | -24.69%25.93K | -24.68%25.93K | -14.46%137.69K | -14.46%34.42K | -14.46%34.42K | -14.45%34.42K | -14.46%34.42K | -35.50%160.96K | -36.58%40.24K |
| Gross profit | 24.68%-25.93K | 24.69%-25.93K | 24.68%-25.93K | 14.46%-137.69K | 14.46%-34.42K | 14.46%-34.42K | 14.45%-34.42K | 14.46%-34.42K | 35.50%-160.96K | 36.58%-40.24K |
| Operating expense | 22.40%551.49K | -23.47%427.03K | -32.72%465.47K | -26.37%2.24M | -45.48%534.93K | -9.80%450.57K | -42.15%558.01K | 17.10%691.88K | -50.35%3.04M | -24.51%981.21K |
| Selling and administrative expenses | -4.26%141.52K | -9.93%136.14K | -40.14%127.41K | -21.66%653.78K | -61.18%141.98K | -2.84%147.81K | -2.40%151.15K | 31.56%212.85K | 9.09%834.52K | 98.09%365.76K |
| -General and administrative expense | -4.26%141.52K | -9.93%136.14K | -40.14%127.41K | -21.66%653.78K | -61.18%141.98K | -2.84%147.81K | -2.40%151.15K | 31.56%212.85K | 9.09%834.52K | 98.09%365.76K |
| Research and development costs | --0 | 10.89%11.09K | ---- | ---- | ---- | --0 | --10K | ---- | ---- | ---- |
| Other operating expenses | 35.41%409.97K | -29.50%279.8K | -29.43%338.06K | -28.16%1.58M | -34.47%403.45K | -12.85%302.76K | -50.98%396.87K | 11.65%479.03K | -58.85%2.2M | -44.78%615.72K |
| Operating profit | -19.06%-577.41K | 23.54%-452.96K | 32.34%-491.4K | 25.77%-2.37M | 44.26%-569.35K | 10.15%-484.99K | 41.04%-592.44K | -15.09%-726.3K | 49.76%-3.2M | 25.07%-1.02M |
| Net non-operating interest income (expenses) | -95.55%13 | -75.00%1 | 200.00%3 | -50.00%1 | -97.19%8 | -87.88%292 | 105.00%4 | |||
| Non-operating interest income | ---- | ---- | ---- | -95.55%13 | -75.00%1 | 200.00%3 | -50.00%1 | -97.19%8 | -87.88%292 | 105.00%4 |
| Other net income (expenses) | 170.85%18.6K | 250.79%9.31K | -183.76%-8.49K | 92.32%46.35K | 891.46%68.64K | -145.01%-26.24K | 71.79%-6.18K | 378.25%10.13K | 246.24%24.1K | -199.13%-8.67K |
| Gain on sale of security | 170.85%18.6K | 250.79%9.31K | -183.76%-8.49K | 92.32%46.35K | 891.46%68.64K | -145.01%-26.24K | 71.79%-6.18K | 378.25%10.13K | 246.24%24.1K | -199.13%-8.67K |
| Income before tax | -9.31%-558.82K | 25.89%-443.64K | 30.20%-499.89K | 26.66%-2.33M | 51.39%-500.7K | -6.19%-511.24K | 41.69%-598.61K | -12.88%-716.17K | 50.26%-3.17M | 23.95%-1.03M |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -9.31%-558.82K | 25.89%-443.64K | 30.20%-499.89K | 26.66%-2.33M | 51.39%-500.7K | -6.19%-511.24K | 41.69%-598.61K | -12.88%-716.17K | 50.26%-3.17M | 23.95%-1.03M |
| Net income continuous operations | -9.31%-558.82K | 25.89%-443.64K | 30.20%-499.89K | 26.66%-2.33M | 51.39%-500.7K | -6.19%-511.24K | 41.69%-598.61K | -12.88%-716.17K | 50.26%-3.17M | 23.95%-1.03M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -9.31%-558.82K | 25.89%-443.64K | 30.20%-499.89K | 26.66%-2.33M | 51.40%-500.69K | -6.19%-511.24K | 41.69%-598.61K | -12.88%-716.17K | 50.26%-3.17M | 23.95%-1.03M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -9.31%-558.82K | 25.89%-443.64K | 30.20%-499.89K | 26.66%-2.33M | 51.40%-500.69K | -6.19%-511.24K | 41.69%-598.61K | -12.88%-716.17K | 50.26%-3.17M | 23.95%-1.03M |
| Diluted earnings per share | 0 | 0 | 0 | 0.00%-0.01 | 0 | 0 | 0 | 0 | 66.67%-0.01 | 0 |
| Basic earnings per share | 0 | 0 | 0 | 0.00%-0.01 | 0 | 0 | 0 | 0 | 66.67%-0.01 | 0 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.